Tumor suppressor proteins must be exquisitely regulated since they can induce cell death while preventing cancer. For example, the p19 ARF tumor suppressor (p14 ARF in humans) appears to stimulate the apoptotic function of the p53 tumor suppressor to prevent lymphomagenesis and carcinogenesis induced by oncogene overexpression. Here we present a genetic approach to defining the role of p19 ARF in regulating the apoptotic function of p53 in highly proliferating, homeostatic tissues. In contrast to our expectation, p19 ARF did not activate the apoptotic function of p53 in lymphocytes or epithelial cells. These results demonstrate that the mechanisms that control p53 function during homeostasis differ from those that are critical for tumor suppression. Moreover, the Mdm2/p53/p19 ARF pathway appears to exist only under very restricted conditions.
Activation of growth arrest and apoptotic pathways by the p53 tumor suppressor pathway promotes the removal of tumorigenic cells, thus protecting against cancer in humans and mice (3) . In contrast, activation of these same pathways in homeostatic, nontumorigenic cells can have undesired consequences, including organ atrophy (11) or, in the extreme, embryonic lethality (6, 13) . Presently, a wide range of approaches is being explored to increase p53 activity in human tumors while sparing healthy cells. Critical to the rational design of such therapies is an understanding of the regulation of p53 function in homeostatic tissues. However, to date there is little information on the mechanisms regulating p53 function in intact tissues.
Mdm2 is a proximal regulator of the p53 tumor suppressor in both healthy and tumorigenic cells (4, 11) . The mdm2 gene possesses two separate promoters, an upstream, p53-independent promoter (P1) and a downstream, p53-responsive promoter (P2) (2) . Although mdm2 is a transcriptional target of p53, 80 to 90% of basal mdm2 expression in homeostatic tissues is derived from the p53-independent upstream promoter (P1) (10) . As Mdm2 inhibits p53 in these tissues (11) , transcription factors regulating the P1 promoter may indirectly regulate p53. Furthermore, factors that alter the activity of Mdm2 may also indirectly determine the levels or specific activity of the p53 tumor suppressor.
The mdm2 puro allele expresses reduced amounts of mdm2 mRNA and protein due to insertion of a puromycin resistance cassette into intron six of the mdm2 locus (11) . Heterozygous mice expressing one mdm2 puro allele and one mdm2 null allele express approximately 70% less of the p53 inhibitor Mdm2 than do wild-type mice. These mice revealed that the activity of p53 is exquisitely sensitive to the level of Mdm2 in homeostatic tissues, as evidenced by several p53-dependent phenotypic differences between mice expressing different levels of mdm2 (11) . For example, whereas body weights of mdm2 ϩ/Ϫ mice were identical to those of wild-type mice, further reduction of the level of mdm2 from 50 to 30%, such as that observed in mdm2 puro/Ϫ mice, resulted in a 15 to 20% reduction in body weight (11) . In addition, thymi of mdm2 ϩ/Ϫ mice weighed more than those from mdm2 puro/Ϫ mice (see below) and mdm2 ϩ/Ϫ mice were less radiosensitive than mdm2 puro/Ϫ mice (11) . The extreme sensitivity of cells to the level of Mdm2 suggests that mdm2 puro/Ϫ mice lacking either an inhibitor of Mdm2 or an essential activator of p53 would be readily distinguishable from the original mdm2 puro/Ϫ mice, allowing authentication of critical regulators of p53 and Mdm2.
Here we employed a candidate gene approach to investigate whether the p19 ARF tumor suppressor regulates Mdm2 function in homeostatic tissues. p19 ARF has been shown to increase p53 function by inhibiting Mdm2 in cultured cells (20) and to suppress tumorigenesis involving the p53/Mdm2 pathway (4, 15) . We predicted that if p19 ARF inhibits Mdm2 in homeostatic tissues, then deletion of p19 ARF would increase the activity of the residual Mdm2 present in mdm2 puro/Ϫ mice, thereby rescuing the p53-dependent decreases in body weight, thymic weight, and radioresistance. In contrast to our expectation, deletion of p19 ARF did not increase the ability of Mdm2 to inhibit p53 in intact tissues. These results indicate that in rapidly proliferating, homeostatic tissues, p53 is regulated by mechanisms independent of p19 ARF .
MATERIALS AND METHODS
Mice. Mice were housed in a facility approved by the American Association for the Accreditation of Laboratory Animal Care. Characterization of mdm2 puro/Ϫ mice has been described previously (11) . The mdm2 null allele, mdm2 ⌬7-12 , was kindly provided by Steve Jones (6) . Mice carrying a homozygous deletion of p19 ARF (7) were generously provided by Martine Roussel and Charles J. Sherr via Paul Lambert. All mice were on a mixed 129Sv/C57B6 background, and littermates were compared to minimize genetic variation.
Apoptosis assay. Five-micrometer sections of small intestines were stained with the TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling) assay (green) and counterstained with propidium iodide (red) as described previously (11) .
Whole-body irradiation. Mice were irradiated with 10 Gy of whole-body ionizing radiation and monitored for 40 days as described previously (11) .
Northern analysis. Expression of p21 was assessed using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a loading control as described previously (11) . S1 analysis. Induction of mdm2 following whole-body irradiation was carried out as previously described (10) .
Statistics. For most comparisons, the Student t test was used to generate a P value. For the Kaplan Meier curve, the log rank test was used.
RESULTS

To determine whether p19
ARF regulates Mdm2 function in homeostatic tissues, we generated mdm2 ϩ/ϩ and mdm2 or mdm2 puro/Ϫ p19 ARFϩ/ϩ female mice). In contrast, the body weights of mdm2 ϩ/Ϫ mice were indistinguishable from those of wild-type mice (11) , indicating that loss of p19 ARF did not appreciably increase the Mdm2 function that controls body weight through p53.
Thymi of mdm2 puro/Ϫ mice were dramatically decreased in size and weight compared with those of mdm2 ϩ/ϩ mice ( Fig.  2a) . This 2.5-to 3.0-fold reduction in thymic weight is p53 dependent and correlates with a 10-to 20-fold decrease in T-cell number and a two-to fourfold increase in p53-dependent apoptosis (11) . The activity of p53 in the thymus is very sensitive to changes in mdm2 expression, since mdm2 ϩ/Ϫ thymi weigh twofold more than mdm2 puro/Ϫ thymi ( Fig. 2a ) (P Ͻ 0.0005 for female mice and P ϭ 0.001 for male mice). Since both p53 and p19 ARF act as tumor suppressors in T cells (3, 7), we expected p19 ARF loss to lead to a decrease in p53 function as measured by an increase in thymic weight in the mdm2 puro/Ϫ thymus. However, thymic weights from age-and sex-matched mdm2 puro/Ϫ p19 ARFϪ/Ϫ and mdm2 puro/Ϫ p19 ARFϩ/ϩ mice were indistinguishable from each other (P ϭ 0.49 for male mice and P ϭ 0.11 for female mice) (Fig. 2b and c) . Furthermore, these weights were significantly reduced compared to thymic weights of mdm2 ϩ/Ϫ mice (P Ͻ 0.002 for male mice and P Ͻ 0.005 for female mice). These comparisons reveal that loss of p19 ARF did not restore the activity of Mdm2 to levels seen in mdm2 ϩ/Ϫ mice. Thus, despite a proven role in T-cell tumor suppression, p19 ARF does not appear to regulate the functions of either Mdm2 or p53 in homeostatic thymi.
Bone marrow B cells also undergo increased spontaneous, p53-dependent apoptosis in mdm2 puro/Ϫ mice (11) , and p19 ARF functions as a tumor suppressor in bone marrow B cells overexpressing the c-myc oncogene (4 Previous work has demonstrated that the transcriptional transactivation function of p53 was increased in tissues from mdm2 puro/Ϫ mice, as evidenced by a p53-dependent increase in p21 expression (11) . To test whether p19 ARF loss restored the ability of Mdm2 to inhibit the transactivation function of p53, p21 mRNA levels were measured in spleens from wild-type and mdm2 puro/Ϫ mice expressing or lacking p19 ARF . Northern analysis revealed that p19 ARF had little influence on the level of p21 expression (Fig. 4) Mice expressing 30% of the wild-type level of mdm2 live for a significantly shorter time after whole-body ionizing irradiation than do mice expressing 50% of the wild-type level due to p53-mediated radiosensitivity (11) . Although there has been controversy about a role for p19 ARF in regulating p53 in response to ionizing irradiation (8, 9), we reasoned that the exquisite sensitivity of irradiated mice to small changes in mdm2 expression would allow us to detect an influence of p19 ARF on p53 function in mdm2 puro/Ϫ mice. Therefore, we irradiated a cohort of wild-type and mdm2 puro/Ϫ mice expressing or lacking p19 ARF and measured survival. We found no increase in the survival rate in mice lacking p19 ARF . Regardless of p19 ARF status, mdm2 puro/Ϫ mice all died within 12 days of irradiation (P ϭ 0.51) (Fig. 5a) ARF . In agreement with these findings, loss of p19 ARF had no effect on the activation of p53's transcriptional activation function following whole-body ionizing radiation (Fig. 5b) . The p53-responsive mdm2 promoter, P2, was activated 9-to 10-fold following whole-body ionizing irradiation, independent of the p19 ARF gene status, indicating that p19 ARF is not a critical regulator of p53 in the response to DNA damage.
Epithelial cells in the small intestines of mdm2 puro/Ϫ mice undergo a dramatic increase in the frequency of spontaneous p53-mediated apoptosis compared with those in wild-type mice, demonstrating the extreme sensitivity of this cell type to decreases in mdm2 expression (11) . Therefore, we tested whether loss of p19 ARF could decrease the number of apoptotic epithelial cells in the small intestines of mdm2 puro/Ϫ mice. Deletion of p19 ARF did not decrease the number of apoptotic epithelial cells in the intestines of mdm2 puro/Ϫ mice ( Fig. 6a to  d ). There was a 15-fold increase in apoptotic cells in the crypts of mdm2 puro/Ϫ intestines, regardless of p19 ARF gene status (Fig. 6e) , suggesting that p19 ARF does not normally regulate Mdm2 or p53 in this rapidly dividing tissue. Hence, although p19 ARF has been shown to regulate p53-mediated apoptosis in murine skin epithelial cells overexpressing the c-myc oncogene (14) , it does not appear to play a role in the homeostatic epithelial cells of the small intestine.
DISCUSSION
Here we have described results from an epistasis experiment designed to test the importance of p19 ARF in regulating Mdm2 and p53 in several homeostatic tissues. We demonstrate that the propensity of three different cell types to undergo spontaneous p53-dependent apoptosis is not due to inhibition of Mdm2 function by p19 ARF . Thus, p19 ARF does not appear to play a role in the tissue-specific regulation of p53-dependent apoptosis. Furthermore, since p19 ARF is expressed ubiquitously (21), failure of p19 ARF deletion to rescue, even partially, any of the p53-dependent phenotypes seen in mdm2 hypomorphic mice argues against a critical role for p19 ARF in regulating Mdm2 function under normal, physiological conditions, even in a number of highly proliferative tissues.
Although plentiful evidence supports a role for p19 ARF in activating p53 when oncogenes are expressed aberrantly in tissues, p19 ARF does not always contribute to the activation of p53 under such circumstances. For example, whereas loss of p19 ARF decreases the amount of p53-mediated apoptosis induced by c-myc overexpression in murine skin, it has no effect on p53-mediated apoptosis induced by E2F1 overexpression in the same tissue (14) . In addition, p19 ARF does not contribute to the increase in p53-mediated apoptosis caused by expression of a fragment of simian virus 40 large T antigen in the choroid plexus of mice (17) 
, and mdm2 ϩ/ϩ p19 ARFϪ/Ϫ (n ϭ 8) mice following exposure to 10 Gy of whole-body ionizing radiation. (b) p53-dependent induction of mdm2 expression by whole-body ionizing radiation is not enhanced by deletion of p19 ARFϪ/Ϫ . Mice were untreated (lanes 3 to 8) or treated with 5 Gy of ionizing radiation and sacrificed after 4 h (lanes 9 to 14). Total RNA was isolated from the spleens, and the levels of RNAs from the mdm2 P1 and P2 promoters were measured by S1 nuclease protection assay. As a positive control (ϩ), probe was allowed to hybridize to RNA synthesized in vitro from plasmids designed to reflect transcriptional initiation at the mdm2 P1 and P2 promoters (lane 1). As a negative control, the probe alone was incubated with S1 nuclease (lane 2). ARF regulates the p53/Mdm2 pathway appear to be restricted to those in which a form of stress activates p53. For example, p19 ARF regulates p53 in cultured mouse embryo fibroblasts, and p53 becomes activated during culturing (10, 22) . Reactive oxygen species may be one factor common among situations in which p19 ARF regulates p53. Recent work has shown that hydrogen peroxide causes dimerization of p19 ARF and enhances the interaction between p19 ARF and Mdm2 (12) . If the function of p19 ARF that regulates Mdm2 and p53 requires activation, the concentration of reactive oxygen species may influence whether p19 ARF regulates the p53/Mdm2 pathway. Whatever the factor(s) common between situations in which p19 ARF inhibits p53, it seems clear that p14 ARF (human p19 ARF ) does not influence the p53/ Mdm2 pathway in tumors since either the p14 ARF or p53 gene is inactivated in the majority of human cancers (19) . Instead, p19 ARF /p14 ARF seems to regulate p53 under conditions that can lead to tumorigenesis, and during the transformation process the cell loses the ability to regulate p53 through p19 ARF / p14 ARF . Previously it was shown that p53 does not regulate mdm2 expression under homeostatic conditions, although p53 induces mdm2 expression following whole-body irradiation (11) . Thus, it appears that both p53 and p19 ARF regulate Mdm2 only under conditions of stress. The factors that control the basal activity and the level of expression of Mdm2 remain to be elucidated. The mdm2 puro/Ϫ mouse will be a useful tool for this endeavor. 
